Cargando…
Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy
INTRODUCTION: The benefit of annual administration of zoledronic acid in the management of thalassemia-associated osteoporosis is unknown. AIM: The aims of this study were to evaluate the efficacy of treatment with two different dosing regimens of IV zoledronic acid (annually versus every 3 months)...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Medical Sciences of Bosnia and Herzegovina
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021158/ https://www.ncbi.nlm.nih.gov/pubmed/30061760 http://dx.doi.org/10.5455/medarh.2018.72.170-173 |
_version_ | 1783335421027024896 |
---|---|
author | Darvishi-Khezri, Hadi Kosaryan, Mehrnoush Akbarzadeh, Rosseta Aliasgharian, Aily Fazli, Mehran |
author_facet | Darvishi-Khezri, Hadi Kosaryan, Mehrnoush Akbarzadeh, Rosseta Aliasgharian, Aily Fazli, Mehran |
author_sort | Darvishi-Khezri, Hadi |
collection | PubMed |
description | INTRODUCTION: The benefit of annual administration of zoledronic acid in the management of thalassemia-associated osteoporosis is unknown. AIM: The aims of this study were to evaluate the efficacy of treatment with two different dosing regimens of IV zoledronic acid (annually versus every 3 months) for increasing low bone mineral density (BMD) in patients with osteoporosis associated with β-thalassemia as annually and 3-monthly on bone density in patients. MATERIALS AND METHODS: This retrospective, single-center study analyzed patients’ clinical records and bone density measurements. Those enrolled in the study were 14 to 53 years of age, had documented β-thalassemia, and were treated with IV zoledronic acid on either an annual or every 3 months dosing regimen. Dual-energy X-ray absorptiometry was used to obtain the z-score for BMD in the lumbar spine and femoral neck. RESULTS: Thirty-four patients were enrolled in the study; 15 (44.1%) had been treated annually, and 19 (55.9%) had been treated every month. In patients receiving treatment with the once-yearly dose of zoledronic acid, significant increases were observed in the lumbar spine BMD z-score, from -2.45 ± 0.69 to -1.97 ± 0.82 (P=0.02). When comparing BMD across the two treatment regimens, the mean lumbar spine BMD was 0.82 greater (95% CI 0.31, 1.33, P=0.003) and the mean femoral neck BMD 0.37 greater (95% CI -0.15, 0.87, P=0.1) in the group receiving annual zoledronic acid treatment. CONCLUSIONS: In patients with thalassemia-associated osteopenia, annual treatment with zoledronic acid increases lumbar spine bone density while being more effective, less expensive, and associated with fewer adverse events than dosing every 3 months. |
format | Online Article Text |
id | pubmed-6021158 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Academy of Medical Sciences of Bosnia and Herzegovina |
record_format | MEDLINE/PubMed |
spelling | pubmed-60211582018-07-30 Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy Darvishi-Khezri, Hadi Kosaryan, Mehrnoush Akbarzadeh, Rosseta Aliasgharian, Aily Fazli, Mehran Med Arch Original Paper INTRODUCTION: The benefit of annual administration of zoledronic acid in the management of thalassemia-associated osteoporosis is unknown. AIM: The aims of this study were to evaluate the efficacy of treatment with two different dosing regimens of IV zoledronic acid (annually versus every 3 months) for increasing low bone mineral density (BMD) in patients with osteoporosis associated with β-thalassemia as annually and 3-monthly on bone density in patients. MATERIALS AND METHODS: This retrospective, single-center study analyzed patients’ clinical records and bone density measurements. Those enrolled in the study were 14 to 53 years of age, had documented β-thalassemia, and were treated with IV zoledronic acid on either an annual or every 3 months dosing regimen. Dual-energy X-ray absorptiometry was used to obtain the z-score for BMD in the lumbar spine and femoral neck. RESULTS: Thirty-four patients were enrolled in the study; 15 (44.1%) had been treated annually, and 19 (55.9%) had been treated every month. In patients receiving treatment with the once-yearly dose of zoledronic acid, significant increases were observed in the lumbar spine BMD z-score, from -2.45 ± 0.69 to -1.97 ± 0.82 (P=0.02). When comparing BMD across the two treatment regimens, the mean lumbar spine BMD was 0.82 greater (95% CI 0.31, 1.33, P=0.003) and the mean femoral neck BMD 0.37 greater (95% CI -0.15, 0.87, P=0.1) in the group receiving annual zoledronic acid treatment. CONCLUSIONS: In patients with thalassemia-associated osteopenia, annual treatment with zoledronic acid increases lumbar spine bone density while being more effective, less expensive, and associated with fewer adverse events than dosing every 3 months. Academy of Medical Sciences of Bosnia and Herzegovina 2018-06 /pmc/articles/PMC6021158/ /pubmed/30061760 http://dx.doi.org/10.5455/medarh.2018.72.170-173 Text en © 2018 Hadi Darvishi-Khezri, Mehrnoush Kosaryan, Rozita Akbarzadeh, Aily Aliasgharian, Mehran Fazli http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Paper Darvishi-Khezri, Hadi Kosaryan, Mehrnoush Akbarzadeh, Rosseta Aliasgharian, Aily Fazli, Mehran Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy |
title | Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy |
title_full | Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy |
title_fullStr | Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy |
title_full_unstemmed | Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy |
title_short | Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy |
title_sort | administration of intravenous zoledronic acid every 3 months vs. annually in β-thalassemia patients with low bone mineral density: a retrospective comparison of efficacy |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021158/ https://www.ncbi.nlm.nih.gov/pubmed/30061760 http://dx.doi.org/10.5455/medarh.2018.72.170-173 |
work_keys_str_mv | AT darvishikhezrihadi administrationofintravenouszoledronicacidevery3monthsvsannuallyinbthalassemiapatientswithlowbonemineraldensityaretrospectivecomparisonofefficacy AT kosaryanmehrnoush administrationofintravenouszoledronicacidevery3monthsvsannuallyinbthalassemiapatientswithlowbonemineraldensityaretrospectivecomparisonofefficacy AT akbarzadehrosseta administrationofintravenouszoledronicacidevery3monthsvsannuallyinbthalassemiapatientswithlowbonemineraldensityaretrospectivecomparisonofefficacy AT aliasgharianaily administrationofintravenouszoledronicacidevery3monthsvsannuallyinbthalassemiapatientswithlowbonemineraldensityaretrospectivecomparisonofefficacy AT fazlimehran administrationofintravenouszoledronicacidevery3monthsvsannuallyinbthalassemiapatientswithlowbonemineraldensityaretrospectivecomparisonofefficacy |